KOKO Medical Inc. has developed the KOKO™ Device, a catheter-based technology that promotes uterine contractions while simultaneously removing excess blood to manage postpartum hemorrhage. This device addresses the critical issue of uterine atony, which can lead to life-threatening bleeding in women after childbirth.
Funding
$22.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Postpartum hemorrhage (PPH), often caused by uterine atony, is a life-threatening condition where the uterine muscles fail to contract sufficiently after childbirth, leading to excessive bleeding. Current methods may not be sufficient to quickly and effectively manage this condition, resulting in severe complications and a significant maternal mortality rate.
Solution
KOKO Medical has developed the KOKO™ Device, a catheter-based system designed to manage postpartum hemorrhage by simultaneously promoting uterine contractions and removing excess blood. The device directly addresses uterine atony, a primary cause of PPH, by encouraging the uterus to contract and reduce bleeding. This intervention aims to mitigate the risk of severe complications associated with PPH, such as adult respiratory distress syndrome, renal failure, and the need for hysterectomy. By providing a rapid and effective solution, the KOKO™ Device seeks to improve maternal outcomes and reduce the global burden of postpartum hemorrhage.
Target Audience
The primary target audience includes obstetricians, gynecologists, hospitals, and birthing centers focused on improving maternal health outcomes and reducing the incidence and severity of postpartum hemorrhage.
Features
- Catheter-based technology for direct intervention in the uterus.
- Promotes uterine contractions to address uterine atony.
- Simultaneously removes excess blood to manage postpartum hemorrhage.